These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

734 related articles for article (PubMed ID: 27079334)

  • 21. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
    Jiang M; You JHS
    Clin Cardiol; 2017 Oct; 40(10):789-796. PubMed ID: 28683175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies.
    Yoshikawa Y; Shiomi H; Watanabe H; Natsuaki M; Kondo H; Tamura T; Nakagawa Y; Morimoto T; Kimura T
    Circulation; 2018 Feb; 137(6):551-562. PubMed ID: 28982692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial.
    Lee H; Koo BK; Park KW; Shin ES; Lim SW; Rha SW; Bae JW; Jeon DW; Oh SK; Hur SH; Kim BS; Lee JH; Park TH; Lee NH; Kim HS;
    Am Heart J; 2017 Mar; 185():17-25. PubMed ID: 28267471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients).
    Baber U; Li SX; Pinnelas R; Pocock SJ; Krucoff MW; Ariti C; Gibson CM; Steg PG; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Iakovou I; Dangas G; Aquino MB; Sartori S; Chieffo A; Moliterno DJ; Colombo A; Mehran R
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e006144. PubMed ID: 29870385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.
    Garg P; Galper BZ; Cohen DJ; Yeh RW; Mauri L
    Am Heart J; 2015 Feb; 169(2):222-233.e5. PubMed ID: 25641531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
    Cutlip DE; Kereiakes DJ; Mauri L; Stoler R; Dauerman HL;
    JACC Cardiovasc Interv; 2015 Mar; 8(3):404-410. PubMed ID: 25703885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.
    Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC
    Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies.
    Sorrentino S; Claessen BE; Chandiramani R; Guedeney P; Vogel B; Baber U; Rau V; Wang J; Krucoff M; Kozuma K; Ge J; Seth A; Makkar R; Liu Y; Bangalore S; Bhatt DL; Angiolillo DJ; Saito S; Neumann FJ; Hermiller J; Valgimigli M; Mehran R
    Circulation; 2020 Mar; 141(11):891-901. PubMed ID: 31992063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
    Yeh RW; Secemsky EA; Kereiakes DJ; Normand SL; Gershlick AH; Cohen DJ; Spertus JA; Steg PG; Cutlip DE; Rinaldi MJ; Camenzind E; Wijns W; Apruzzese PK; Song Y; Massaro JM; Mauri L;
    JAMA; 2016 Apr; 315(16):1735-49. PubMed ID: 27022822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
    Gilard M; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berland J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Endresen K; Benamer H; Kiss RG; Ungi I; Boschat J; Morice MC
    J Am Coll Cardiol; 2015 Mar; 65(8):777-786. PubMed ID: 25461690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Camaro C; Damen SA; Brouwer MA; Kedhi E; Lee SW; Verdoia M; Barbieri L; Rognoni A; van T Hof AW; Ligtenberg E; de Boer MJ; Suryapranata H; De Luca G
    Am Heart J; 2016 Aug; 178():37-44. PubMed ID: 27502850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
    Rangé G; Yayehd K; Belle L; Thuaire C; Richard P; Cazaux P; Barbou F; Köning R; Chassaing S; Teiger E; Berthier R; Decomis MP; Claudel JP; Delarche N; Brunel P; De Poli F; Dupouy P; Beygui F; Albert F; Collet JP; Montalescot G;
    Arch Cardiovasc Dis; 2014 Apr; 107(4):225-35. PubMed ID: 24794216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI.
    Giustino G; Chieffo A; Palmerini T; Valgimigli M; Feres F; Abizaid A; Costa RA; Hong MK; Kim BK; Jang Y; Kim HS; Park KW; Gilard M; Morice MC; Sawaya F; Sardella G; Genereux P; Redfors B; Leon MB; Bhatt DL; Stone GW; Colombo A
    J Am Coll Cardiol; 2016 Oct; 68(17):1851-1864. PubMed ID: 27595509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention.
    Faggioni M; Baber U; Sartori S; Chandrasekhar J; Cohen DJ; Henry TD; Claessen BE; Dangas GD; Gibson CM; Krucoff MW; Vogel B; Moliterno DJ; Sorrentino S; Colombo A; Chieffo A; Kini A; Farhan S; Ariti C; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
    Circ Cardiovasc Interv; 2019 Apr; 12(4):e007133. PubMed ID: 30998384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
    Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Palmerini T; Stone GW
    Clin Res Cardiol; 2017 Mar; 106(3):165-173. PubMed ID: 27631821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.
    Shah RR; Pillai A; Omar A; Zhao J; Arora V; Kapoor D; Poommipanit P
    Catheter Cardiovasc Interv; 2017 Mar; 89(4):E99-E103. PubMed ID: 27184930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
    Jackson LR; Ju C; Zettler M; Messenger JC; Cohen DJ; Stone GW; Baker BA; Effron M; Peterson ED; Wang TY
    JACC Cardiovasc Interv; 2015 Dec; 8(14):1880-9. PubMed ID: 26718518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation?
    Basaraba JE; Barry AR
    Am J Health Syst Pharm; 2016 May; 73(9):e229-37. PubMed ID: 27099329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study.
    Giustino G; Redfors B; Mehran R; Kirtane AJ; Baber U; Généreux P; Witzenbichler B; Neumann FJ; Weisz G; Maehara A; Rinaldi MJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Dangas GD; Brener SJ; Ozgu Ozan M; Stone GW
    Int J Cardiol; 2017 Nov; 246():20-25. PubMed ID: 28867009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
    Valgimigli M; Patialiakas A; Thury A; McFadden E; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Airoldi F; Ferlini M; Liistro F; Dellavalle A; Vranckx P; Briguori C;
    J Am Coll Cardiol; 2015 Mar; 65(8):805-815. PubMed ID: 25720624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.